Solution

Orcana generates contextual insights and recommendations

Structured data

Sales data
Call and Mktg. activity
HCP Profile
Call-plan

Therapeutic ontology

Pubmed docs (NIH)
drugs.com for competitor
Product label for our brand
Internal clinical-research docs

Unstructured HCP intel

Speaker event (Topic+content)
Rep activity (key-topics)
Marketing engagement
Product website’s click data

Scott:

@ Orcana, tell me about Steve Mark from Adams Oncology Institute?

Steve shows a steep decline in new-patients initiation for Yescarta, but shows an increase in new-patients in market

Rob W. recently called on Steve and spoke about the side-effects of L2 patients with ICD-10 code E11.311

Steve was the keynote speaker for NIH event in San Carlos last month and spoke about evolving treatment pathways with minimizing radiation therapy needs.

Orcana delivers mid-to-high impact analysis, on-demand

Improve Operational Efficiency by Slicing Data, Over Chat

Scott Doe

Role: Sales Rep

Product Basket: A, B, C

((Profile and relevant information of each user is captured during onboarding; can be updated anytime.)

Scott Doe

Give me a list of my target HCPs that had >5 patients last quarter and have not seen new patients this quarter?

Orcana

To confirm, you’re looking for your target HCPs that have 5+ TRXs last quarter and zero this quarter?

Scott Doe

5+ NBRx not TRx. Also, prioritize HCPs that I haven’t called in the last 6 weeks.

Orcana

Here is a list of ~12 HCPs that you haven’t called in the last 6 weeks, and have not initiated new-patients on brand this quarter.
Captured Data: Customer name, address, specialty, target calls, calls till date.
Assumptions
Data-source: IQVIA XPOPD (Data ending: 05/03/2024)
Call Activity: (Data ending: 05/24/2024)
Click here to check the dashboard that captures your territory's call-plan adherence summary for this quarter.

Key Benefits:

✅ Helps improve BI adoption

✅ Users spanning sales reps, sales managers, brand managers, etc., can easily generate custom lists or summaries

✅ Orcana will access a predefined scope of data-sources, metrics, and segments (customer, product, and patient segments)

Dive deep into trend break contributors, instantaneously

Jane Sturgis

Role: Analytics Lead

Business Unit: Immunology

Brand: A

Orcana

New-patient growth (NBRx) for Brand A decreased WoW by ~14%. Should I look into what drove this decrease?

Jane :

Yes

Orcana

Tier A, Tier B, Tier C HCPs contribute to 65%, 30%, and 5% of this NBRx decline.

Jane:

Summarize Tier A NBRx decliners

Orcana

Tier A showed ~4.1 fewer switch-patients/HCP WoW
Within Tier A, Trialist segment that weren’t called this quarter showed a steep decline of ~80% WoW.

Assumptions:

Data-source: IQVIA NPA (Data ending: 05/24/2024); Call Activity (Data ending: 05/24/2024)

Insights Box:

Orcana tracks trend-breaks and promptly alerts to initiate a deep-dive

Key Benefits:

✅ Orcana is continuously sifting through the data to flag any trend-breaks across several KPIs and segments

✅ Orcana analyzes trend-break across an exhaustive list of entities and summarizes key-patterns in a succinct manner

Uncover insights through ad hoc analysis and follow-ups

Austin Mac

Role: Marketing Manager

Business Unit: Immunology

Brand: A

Austin :

Which products drove the decline in brand ‘X’s share among Tier A HCPs in the last quarter?

Orcana

While market TRx increased by ~6% QoQ, brand ‘X’ decrease in share of ~12%pts was driven by brands P and Q.  
Here is a summary:  
- P’s share went up to 39% (+6%pts QoQ)  
- Q’s share went up to 24% (+3%pts QoQ)  
Assumptions: Data-source: IQVIA NPA (Data ending: 05/24/2024); Call Activity (Data ending: 05/24/2024)

Orcana

Would you want to know more about HCPs that are growing steeply for Product P and Q?

Austin:

Yes, summarize these HCPs by call activity and district.

Key Benefits:

✅ Scope includes creating quick segments (custom deciling), cross-tabs, correlation-plots, etc.

✅ Orcana will analyze a predefined scope of data-sources, metrics and segments (customer, product and patient segments)

Analyze at a cohort-level for valuable treatment patterns

John Quimby

Role: Forecasting Manager

Business Unit: Immunology

Brand: A

John :

Has L1 patients’ duration on therapy increased over the past 12 months?

Orcana

Yes, L1 patients’ duration on therapy has increased by ~18% in the latest 6 months, compared to prior 6 months.   On an average, L1 patient cohorts are on therapy for ~85 days (+15 days compared to prior 6 months).   Assumptions: Data-source: IQVIA LAAD (Data ending: 03/31/2024); Look-forward period: 6 months; Latest cohort: 7/1/23 to 12/31/23; Prior cohort: 1/1/23 to 6/30/23)

Orcana

Would you want to know share of products from patients that are on L1 for longer duration in latest cohort?

John:

No, instead summarize product share of L1 patients before they switched to L2 in the last 6 months.

Key Benefits:

✅ Orcana is designed to run cohort-level analysis to surface any deep insights by adhering to aligned business rules.

✅ Metrics spanning duration on therapy, refill rate trends, switch patterns, etc. across several segments can be analyzed.

Improve Operational Efficiency by Slicing Data, Over Chat

Dive deep into trend break contributors, instantaneously

Uncover insights through ad hoc analysis and follow-ups

Analyze at a cohort-level for valuable treatment patterns

Life Sciences

MetricMap™ enables efficient trend diagnosis at scale

Why did Brand TRx for last month decrease?

Data is always secure and is never exposed to external APIs

Orcana ensures data privacy by keeping all processing in-house, never exposing raw data to external APIs while providing accurate and explicable insights.

Orcana delivers mid-to-high impact analysis, on-demand

With Orcana, you uncover insights instantaneously

MetricMap™ enables root-cause analysis

Data is always secure and is never exposed to external APIs

Orcana ensures data privacy by keeping all processing in-house, never exposing raw data to external APIs while providing accurate and explicable insights.

Our Solutions

Orcana generates contextual insights and recommendations

Structured data

Therapeutic ontology

Unstructured HCP intel

Scott:

Orcana delivers mid-to-high impact analysis, on-demand

Improve Operational Efficiency by Slicing Data, Over Chat

Scott Doe

Scott Doe

Orcana

Scott Doe

Orcana

Key Benefits:

Dive deep into trend break contributors, instantaneously

Jane Sturgis

Orcana

Jane :

Yes

Orcana

Jane:

Orcana

Assumptions:

Insights Box:

Key Benefits:

Uncover insights through ad hoc analysis and follow-ups

Austin Mac

Austin :

Orcana

Orcana

Austin:

Key Benefits:

Analyze at a cohort-level for valuable treatment patterns

John Quimby

John :

Orcana

Orcana

John:

Key Benefits:

Improve Operational Efficiency by Slicing Data, Over Chat

Dive deep into trend break contributors, instantaneously

Uncover insights through ad hoc analysis and follow-ups

Analyze at a cohort-level for valuable treatment patterns

MetricMap™ enables efficient trend diagnosis at scale

Data is always secure and is never exposed to external APIs

Orcana delivers mid-to-high impact analysis, on-demand

With Orcana, you uncover insights instantaneously

MetricMap™ enables root-cause analysis

Data is always secure and is never exposed to external APIs

Get started.